BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

Core Insights - BioVie Inc. announced significant improvements in both non-motor and motor symptoms for Parkinson's Disease patients treated with bezisterim compared to those on placebo, indicating the potential of bezisterim as an adjunct therapy to levodopa [1][4] Group 1: Study Findings - The Phase 2a trial data presented at the XXIX World Congress on Parkinson's Disease showed that bezisterim-treated patients had a -2.8 point advantage on the MDS-UPDRS Motor score compared to placebo [3] - In patients younger than 70 years, the advantage increased to -4.7 points, with 30% of bezisterim-treated patients showing improved morning Part 3 scores, while none in the placebo group showed similar improvements [3] - Bezisterim-treated patients experienced a significant improvement of -2.4 points in the sleep/fatigue domain of the NMSS, while placebo patients worsened by +1.0 points [3] Group 2: Mechanism and Potential - Bezisterim is an orally bioavailable, BBB-permeable insulin-sensitizer with anti-inflammatory properties, showing potential to reduce symptoms of long COVID and modulate inflammation [5] - The drug is being investigated for both Alzheimer's disease and Parkinson's disease, with previous studies indicating improvements in motor control and cognition [6][7] Group 3: Company Overview - BioVie Inc. is focused on developing innovative drug therapies for neurological and neurodegenerative disorders, with bezisterim targeting neuroinflammation and insulin resistance [8] - The company is also evaluating BIV201 for advanced liver disease, which has received FDA Fast Track status [8]